Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
The Rogers Foundation announces a second landmark gift, building on its $130 million gift in 2014, to sustain the Ted Rogers Centre for Heart Research in perpetuity and bring the promise of precision cardiac health to patients across Canada and globally. In 2014, the...
Ted Rogers Chair in Heart Function Outcomes Dr. Douglas Lee leads new Heart-Brain Connection $3 million IMPACT Award project
Four unique educational events in October and December
Targeting heart failure in Indigenous communities
Our funded study reveals inequitable COVID-19 rates from the start
Please join us for an ECHO webinar on Tuesday June 15, 2021 (11 am – 12 pm EST) featuring Dr. Gavin Oudit (Founder & Chief Operating Officer, PEARKO Therapeutics Inc.; Professor, Department of Medicine, University of Alberta; Clinician-Scientist, Mazankowski Alberta Heart Institute; Director, Heart Function Clinic; Canada Research Chair in Heart Failure).
Dr. Oudit’s presentation entitled, “Apelin Analogs as Novel Biologics for Cardiovascular Disease”, will feature an overview of PEARKO Therapeutics, its technologies and the story behind its success. PEARKO Therapeutics is a biopharmaceutical company engaged in the practice of translational medicine: catalyzing and driving the translation of molecular discoveries to patients. PEARKO Therapeutics has established itself in the field of cardiovascular medicine with its highly effective and highly versatile biologic: apelin analog therapy.
Register in advance for this meeting: https://us02web.zoom.us/meeting/register/tZcqc-GqqjIiH9XHnsx3G6KM0FXUTbmBcfTH
After registering, you will receive a confirmation email containing information about joining the webinar.
ECHO is an entrepreneurship training program, funded and organized in a partnership between (i) the Translational Biology and Engineering Program (TBEP), the University of Toronto component of the Ted Rogers Centre for Heart Research, and (ii) the Health Innovation Hub (H2i).
